Is Bristol Myers Squibb Company (BMY) a Good Buy at the Moment?

Bristol Myers Squibb (BMY): Recent Performance Overview

Bristol Myers Squibb (BMY) has recently attracted significant attention from investors. To better understand its short-term outlook, let's examine some of the main factors that could influence the stock's movement in the near future.

Over the past month, shares of this biopharmaceutical company have declined by 2.7%, mirroring the performance of both the Zacks S&P 500 composite and the Medical - Biomedical and Genetics sector. The key question now is: what direction might the stock take next?

Key Drivers of Stock Movement

While news headlines or speculation can cause short-term volatility, long-term investment decisions are typically shaped by fundamental factors. Among these, changes in earnings forecasts are especially important.

Updates on Earnings Projections

At Zacks, the primary focus is on shifts in a company's earnings outlook, as the present value of future earnings is a major determinant of a stock's fair value. When analysts revise their earnings estimates upward, it often signals improved business prospects, which can attract buyers and push the stock price higher. Research consistently shows a strong link between earnings estimate revisions and short-term stock price trends.

• For the current quarter, Bristol Myers is projected to earn $1.46 per share, a decrease of 18.9% compared to the same quarter last year. Over the past 30 days, the consensus estimate has dropped by 2.8%.
• For the full fiscal year, the consensus estimate stands at $6.26 per share, reflecting a 1.8% increase from the previous year. This estimate has risen by 3.3% in the last month.
• Looking ahead to the next fiscal year, the consensus estimate is $6.07 per share, which is 3% lower than the current year's expected results. This estimate has also increased by 3.3% over the past 30 days.

Zacks' proprietary stock rating system, the Zacks Rank, leverages these earnings estimate changes and other related factors to provide a clear view of a stock's near-term potential. Bristol Myers currently holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market.

12-Month EPS Trend

The chart below illustrates the changes in Bristol Myers' forward 12-month consensus EPS estimate:

Revenue Growth Outlook

Consistent revenue growth is essential for sustained earnings expansion. For the current quarter, analysts expect Bristol Myers to generate $10.86 billion in sales, a 3% decline from the same period last year. The consensus sales estimates for the current and next fiscal years are $47.02 billion and $45.92 billion, representing year-over-year decreases of 2.4% and 2.3%, respectively.

Recent Financial Results and Surprises

In the most recent quarter, Bristol Myers reported revenue of $12.5 billion, up 1.3% from a year earlier. Earnings per share came in at $1.26, compared to $1.67 in the prior year. These results exceeded the Zacks Consensus Estimate for revenue by 2.03% and for EPS by 9.57%. Notably, the company has surpassed consensus EPS and revenue estimates in each of the last four quarters.

Valuation Insights

Evaluating a stock's valuation is crucial for making informed investment decisions. Comparing valuation multiples like price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) to historical averages and industry peers helps determine whether a stock is undervalued, fairly valued, or overvalued.

The Zacks Value Style Score, which grades stocks from A to F based on a range of valuation metrics, currently assigns Bristol Myers an A. This suggests the stock is trading at a discount relative to its peers.

Conclusion

The analysis above, along with additional resources available on Zacks.com, can help investors decide whether to pay attention to the current market interest in Bristol Myers. With a Zacks Rank #3, the stock is expected to perform similarly to the overall market in the near term.